Ozbun Michelle Adair PhD

Dr. Ozbun has disclosed three inventions, received one issued U. S. patent and has two pending patent applications. Dr. Ozbun has a sponsored research agreement with Novartis AG and interest from several other pharmaceutical companies in her human papillomavirus technologies. Dr. Ozbun and her co-inventors have discovered antagonist compounds that are viable candidates for prevention of infection by HPVs. Additionally, the compounds can inhibit binding and uptake of other microorganisms—whether viral or bacterial—prior to cellular uptake (including, but not necessarily limited to, HIV, herpes simplex, and Chlamydia). Dr. Ozbun has also made breakthrough discoveries related to functional inhibitor compounds that cause diminished HPV early gene expression and cell signaling.

Publications:
1. Dziduszko, A. and M.A. Ozbun. 2013. Annexin A2 and S100A10 Regulate Human Papillomavirus Type 16 Entry and Intracellular Trafficking in Human Keratinocytes, J. Virol., 87(13):7502-7515. 2. Surviladze, Z., R. T. Sterk, S. A. De Haro, and M. A. Ozbun. 2013. Cellular Entry of Human Papillomavirus Type 16 Involves Activation of the PI3K/Akt/mTOR Pathway and Inhibition of Autophagy. J Virol, 87:2508-2517. 3. Surviladze Z, Dziduszko A, and M. A. Ozbun. 2012. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. Feb;8(2):e1002519. Epub 2012 Feb 9.